Slingshot members are tracking this event:
Immunomedics (IMMU) Expects to Complete Phase 3 Trial Design for IMMU-130 in Metastatic Colorectal Cancer in early 2017
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Mar 21, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3 Trial Design, 2016, Immu-130